Please use this identifier to cite or link to this item:
Title: Narrow-leafed lupin (Lupinus angustifolius L.) β-conglutin proteins modulate the insulin signalling pathway as potential type 2 diabetes treatment and inflammatory-related disease amelioration
Austin Authors: Lima-Cabello, Elena;Alche, Victor;Foley, Rhonda C;Andrikopoulos, Sofianos;Morahan, Grant;Singh, Karam B;Alche, Juan D;Jimenez-Lopez, Jose C
Affiliation: Deptartment of Biochemistry, Cell & Molecular Biology of Plants, Granada, Spain
Estacion Experimental del Zaidin, Spanish National Research Council (CSIC), Granada, Spain
Andalusian Health System, Health Center "Villanueva de las Torres", Granada, Spain
The Commonwealth Scientific and Industrial Research Organisation (CSIRO), CSIRO - Agriculture and Food, Centre for Environment and Life Sciences (CELS), Floreat, Western Australia, Australia
Department of Medicine, Heidelberg Repatriation Hospital, Austin Health, The University of Melbourne, Heidelberg West, Victoria, Australia
Harry Perkins Institute of Medical Research, Centre for Diabetes Research, The University of Western Australia, Crawley, Western Australia, Australia
The UWA Institute of Agriculture, The University of Western Australia, Crawley, Western Australia, Australia
Issue Date: 24-Dec-2016
Date: 2016-12-24
Publication information: Molecular Nutrition and Food Research 2016; online first: 24 December
Abstract: SCOPE: We have investigated the potential use of β-conglutin protein isoforms from narrow-leafed lupin (Lupinus angustifolius L.) as a diabetes treatment. METHODS AND RESULTS: We produced purified recombinant β1-, β2-, β3-, β4-, and β6-conglutin proteins and showed that β1, β3 and β6 could bind to insulin. To assess β-conglutin proteins modulatory effect on insulin-activation meditated kinases, whole blood and peripheral blood mononuclear cell (PBMC) cultures from Type 2 diabetes (T2D) and healthy control subjects (C) were incubated with conglutin proteins. Treatment of PBMCs from T2D patients with β1, β3, and β6 proteins increased up to 3-folds mRNA and protein levels of genes important in insulin signalling pathways, namely IRS-1/p85 /AKT/GLUT-4. This was accompanied by a comparable fold-change decrease in the mRNA expression level of pro-inflammatory genes (iNOS and IL-1β) and proteins compared to healthy controls. The β2 and β4 isoforms had no effect on the insulin signalling pathway. However, these β-conglutin proteins elicited pro-inflammatory effects since levels of mRNA and proteins of iNOS and IL-1β were increased. CONCLUSION: Our results raise the possibility of using these particular β-conglutin proteins in the prevention and treatment of diabetes, as well as their potential as anti-inflammatory molecules.
DOI: 10.1002/mnfr.201600819
Journal: Molecular Nutrition and Food Research
PubMed URL:
Type: Journal Article
Subjects: Anti-inflammatory
Sweet lupins
Type 2 Diabetes
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 10, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.